Strides Shasun soars on receiving USFDA approval for Amantadine Hydrochloride Capsules

08 Jun 2017 Evaluate

Strides Shasun is currently trading at Rs. 957.60, up by 21.05 points or 2.25% from its previous closing of Rs. 936.55 on the BSE.

The scrip opened at Rs. 944.70 and has touched a high and low of Rs. 964.75 and Rs. 936.30 respectively. So far 16408 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1259.00 on 03-Feb-2017 and a 52 week low of Rs. 848.50 on 24-May-2017.

Last one week high and low of the scrip stood at Rs. 970.00 and Rs. 925.60 respectively. The current market cap of the company is Rs. 8428.12 crore.

The promoters holding in the company stood at 31.09%, while institutions and non-institutions held 48.89% and 20.02% respectively.

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Amantadine Hydrochloride Capsules USP, 100 mg. The product received approval in 15 months under the new GDUFA regime.

The US market for this product is around $25 million with three generic players, as per IMS data. The product will be launched immediately.

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.

Strides Pharma Scien Share Price

806.70 10.50 (1.32%)
29-Jan-2026 13:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1596.05
Dr. Reddys Lab 1198.50
Cipla 1317.50
Zydus Lifesciences 887.00
Lupin 2118.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×